Eli Lilly and Company (NYSE:LLY) Shares Climb 3.8% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price rose 3.8% during trading on Wednesday. The company traded as high as $1,213.82 and last traded at $1,211.1430. Approximately 377,091 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 2,939,294 shares. The stock had previously closed at $1,166.51.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity and diabetes momentum: RBC expects Lilly could raise its full-year revenue outlook, supported by continued sales of Zepbound and other cardiometabolic products. Retatrutide is also viewed as a potentially larger future growth driver, with investor attention likely to intensify ahead of the company’s October 29 earnings report. RBC expects Lilly to raise revenue outlook
• Positive Sentiment: Favorable earnings expectations: Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. Analysts are also anticipating continued earnings growth in the upcoming third-quarter report. Eli Lilly earnings preview
• Positive Sentiment: Pipeline expansion: Lilly’s collaboration with Prelude Therapeutics will test an experimental breast-cancer drug in combination with established therapies, adding to its oncology pipeline. Broader industry cancer-drug spending is projected to exceed $400 billion by 2028, supporting long-term opportunity. Prelude clinical trial collaboration
• Neutral Sentiment: Valuation remains a key debate: Commentary highlights Lilly’s exceptional growth and potential undervaluation relative to its outlook, but the stock trades at a premium multiple, making execution and pipeline results important.
• Negative Sentiment: Clinical risks remain: A study of a combination involving Zepbound produced greater weight loss but substantially higher discontinuation rates, raising questions about tolerability and commercial adoption. Zepbound combination study

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Sanford C. Bernstein upped their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 23rd. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 26th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Trading Up 3.9%

The company’s 50 day simple moving average is $1,176.60 and its two-hundred day simple moving average is $1,102.08. The company has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 1.52 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 34.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. Insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $13,522,666,000. Jupiter Topco LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $4,667,180,000. Fifth Third Bancorp lifted its holdings in Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Eli Lilly and Company by 353.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after buying an additional 1,208,510 shares in the last quarter. Finally, Corient Private Wealth LP acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $764,116,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.